The Food and Drug Administration (FDA) recently approved Tracleer, a new oral medication for the treatment of pulmonary arterial hypertension (PAH), a rare but fatal type of high blood pressure. PAH causes abnormally high blood pressure in the arteries connecting the heart and lungs.
Tracleer, made by Actelion Pha